The following tables present the fair value and the location of derivative contracts reported on the condensed consolidated balance sheets (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Derivative Assets | | Derivative Liabilities | June 30, 2025 | | Balance Sheet Location | | Fair Value (1) | | Balance Sheet Location | | Fair Value (1) | | | | | | | | | | | | | | | | | | | | Derivatives Not Designated as Hedging Instruments: | Capped call derivatives (2025 Notes) | | Prepaid expenses and other current assets | | $ | 1,303 | | | | | | Capped call derivatives (2029 Notes) | | Long-term derivative assets | | 21,658 | | | | | | Embedded derivative (2025 Notes) | | | | | | Accrued liabilities and other | | $ | 1,363 | | Embedded derivative (2029 Notes) | | | | | | Long-term derivative liabilities | | 48,093 | | FX derivative contracts | | Prepaid expenses and other current assets | | 9,373 | | | Accrued liabilities and other | | 6 | | Total derivatives not designated as hedging instruments | | | | $ | 32,334 | | | | | $ | 49,462 | | | | | | | | | | |
(1)For the classification of inputs used to evaluate the fair value of LivaNova’s derivatives, refer to “Note 3. Fair Value Measurements.” | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Derivative Assets | | Derivative Liabilities | December 31, 2024 | | Balance Sheet Location | | Fair Value (1) | | Balance Sheet Location | | Fair Value (1) | Derivatives Not Designated as Hedging Instruments: | Capped call derivatives (2025 Notes) | | Prepaid expenses and other current assets | | $ | 2,624 | | | | | | Capped call derivatives (2029 Notes) | | Long-term derivative assets | | 23,735 | | | | | | Embedded derivative (2025 Notes) | | | | | | Accrued liabilities and other | | $ | 2,915 | | Embedded derivative (2029 Notes) | | | | | | Long-term derivative liabilities | | 51,819 | | FX derivative contracts | | Prepaid expenses and other current assets | | 738 | | | | | | Total derivatives not designated as hedging instruments | | | | $ | 27,097 | | | | | $ | 54,734 | |
(1)For the classification of inputs used to evaluate the fair value of LivaNova’s derivatives, refer to “Note 3. Fair Value Measurements.”
|